The FDA has cleared Bristol-Myers Squibb's and Sanofi's Plavix anti-clotting drug for reducing the risk of fatal heart attack and the risk of a recurrent heart attack, stroke or death in patients with acute STEMI. Patients who have survived a STEMI incident, the most severe form of heart attack, are at higher risk of another heart attack, stroke or death.

Related Summaries